Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPET-TBI: Methylphenidate in Chronic TBI
NCT02225106Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Aug 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylphenidate hydrochloride extended-release chewable tablet in traumatic brain injury (TBI), sponsored by University of Pennsylvania. Primary endpoint: Change in Perceptual Organization and Processing Speed Index at 4 weeks. Started Aug 2014; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT02225106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225106.